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ABSTRACT
Introduction: Although the spectrum of fungi causing bloodstream fungal infections continues 
to expand, Candida spp. remains responsible for the majority of these cases. Objective: The 
purpose of this study was to characterize the candidemia epidemiology, species distribution and 
antifungal susceptibility patterns at a Brazilian tertiary teaching public hospital with 2,500 beds. 
Methods: Records from the microbiology laboratory were used to identify patients with positive 
blood cultures during 2006. The in vitro activity of amphotericin B, caspofungin, itraconazole, 
fluconazole, voricanozole, and posaconazole were determined using the Etest method. Results: 
One hundred and thirty-six cases of candidemia were identified and 100 strains were available 
for antifungal susceptibility testing. The overall incidence of candidemia was 1.87 cases/1.000 
admissions and 0.27 cases/1.000 patient-days. Among the patients, 58.1% were male, and the 
median age was 40 years old. C. albicans was the most common species (52.2%), followed by C. 
parapsilosis (22.1%), C. tropicalis (14.8%), and C. glabrata (6.6%). All strains were susceptible to 
amphotericin B with a MIC
90
 of 0.5 µg/mL. Overall susceptibility for voriconozole, fluconazole, 
and caspofungin was ≥ 97% with a MIC
90
 of 0.064, 4.0 and 1.0 µg/mL, respectively. For itracona-
zole the susceptibility rate was 81% with a MIC
90
 of 0.5 µg/mL. Posaconazole also demonstrated 
good in vitro activity with a MIC
90
 of 0.25 µg/mL. Conclusion: This is the first antifungal sus-
ceptibility report in our institution.
Keywords: candidemia, Candida spp, susceptibility testing, Candida epidemiology, Candida Etest, 
antifungal susceptibility profi le, Candida antifungal agents, azoles.
[Braz J Infect Dis 2010;14(5):441-448]©Elsevier Editora Ltda.
INTRODUCTION
During the past decades, publications have 
documented an increase in health care as-
sociated fungal infections in different pa-
tient populations.1 A recent study of the 
epidemiology of sepsis found that the an-
nual number of cases caused by fungal or-
ganisms in the United States increased by 
207% between 1979 and 2000.2 Although 
the spectrum of fungi causing bloodstream 
infections has increased, Candida spp. re-
mains the most common agent of such in-
fections accounting for approximately 80% 
of cases.3-6 As candidemia carries a high 
morbidity and mortality rate1,4 various an-
tifungal agents have been preemptively or 
prophylactically used in routine care of 
high-risk patient populations.1,7 However, 
the widespread use of antifungal agents 
raises concerns about their potential eco-
logical effects in selecting and spreading re-
sistant fungal strains or species. There have 
been many reports of breakthrough fungal 
infections with strains showing intrinsic or 
acquired resistance to the exposed drug.8-12 
The antifungal susceptibility testing (AFST) 
helps clinicians in choosing the appropri-
ate antifungal therapy. Currently, the AFST 
reference methodology for Candida spp. 
is a broth dilution proposed by the Clini-
cal Laboratory Standards Institute (CLSI). 
Susceptibility breakpoints are available for 
fluconazole, itraconazole, voriconozole, and 
echinocandins.13 This methodology is extreme-
ly time consuming and diffi cult to perform 
in routine practice at clinical laboratories. 
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AFST commercial systems like Etest strips (AB Biodisk, 
Sweden) have good categorical consistency with the refer-
ence method and is a validated alternative methodology to 
perform routine AFST.14-20
In Brazil candidemia data and antifungal suscepti-
bility patterns of associated strains are still sparse. In 
our institution we record the occurrence of cases candi-
demia of since 1996 (data not shown). In 2006, as there 
was an increase in the occurrence of Candida from blood 
cultures, we then started a project to monitor the resist-
ance patterns during this period. The aim of this study 
was to evaluate the epidemiology of candidemia, spe-
cies distribution, and susceptibility profile over one year 
at our institution, the largest Brazilian tertiary teaching 
hospital.
METHODS
The study was conducted at the Hospital das Clínicas da 
Faculdade de Medicina da Universidade de São Paulo 
(HC), a 2,500 bed tertiary teaching complex, located in 
the city of São Paulo, Brazil, that provides care for a var-
ied population, including immunosuppressed patients. 
The HC Complex is mainly comprised of five hospitals at-
tached to the Universidade de São Paulo Medical School, 
including a general hospital, and other facilities special-
ized in heart diseases, a pediatric hospital, an orthopedic 
and a psychiatric hospital, with overall 1,975 ward beds 
and 325 intensive care unit (ICU) beds.
Case Definition
Records from the microbiology laboratory were used to 
identify patients with positive peripheral blood cultures 
for Candida species from January 1st to December 31st, 
2006. Candidemia was defined as the isolation of Can-
dida spp. from blood culture (one isolate per patient). A 
new episode was considered as the identification of the 
same Candida species more than 30 days after the first 
positive blood culture or finding a new Candida species. 
Cases were reviewed using a standardized data extrac-
tion form observing demographic data, underlying dis-
eases, and patient hospital location at the time of the 
first positive blood culture.
Organism identification
Blood cultures were monitored using an automated cul-
ture system (Bactec 9240 System, Becton, Dickinson, 
USA). Isolates were stored frozen in BHI with 20% glyc-
erol and 0.2% agar at -70°C. Stored strains were sub-
cultured onto potato dextrose agar (Remel, USA) and 
chromogenic media for Candida species (CHROMagar 
Microbiology, USA) to ensure purity. Germ tube test, 
growth at 42°C, assimilation test by API 20C AUX (bi-
oMerieux, French) and microscopy features in cornmeal 
Tween 80 medium (Oxoid, USA) were used for specie 
identification confirmation.
Susceptibility testing
Antifungal susceptibility testing was performed using 
the Etest method (AB BIODISK, Sweden) according to 
the manufacturer’s instructions. The following drugs 
were tested: amphotericin B, caspofungin, fluconazole, 
itraconazole, voriconazole, and posaconazole. A 150 mm 
commercial agar plate (Probac, Brazil) containing RPMI 
1640 medium supplemented with 2% glucose buffered 
with MOPS in a pH of 7.0 was used. The inocula suspen-
sion was adjusted with a spectrophotometer to match 
the transmittance produced by a 0.5 McFarland den-
sity standard at a 530 nm wavelength. The agar surface 
was inoculated using a nontoxic swab according to the 
manufactures instructions. Etest strips were applied af-
ter excess moisture was absorbed and the agar surface 
was completely dry. The plates were incubated at 35°C 
and the MIC (µg/mL) was read after 24 hours. The MIC 
(µg/mL) was read as the lowest concentration at which 
the border of the elliptical zone of growth inhibition in-
tersected the scale on the Etest strip. For the azoles and 
caspofungin, an 80% growth inhibition was used as the 
MIC endpoint, and for amphotericin B, nearly complete 
growth inhibition (100%) was used according to manu-
facture instructions. For MICs that yielded results fall-
ing in between conventional serial twofold dilution, the 
next highest dilution was assigned.
Category MIC breakpoints (BP)
Interpretations for fluconazole, itraconazole, vorico-
nazole and caspofungin were according M27A3, 2008 
CLSI document, 2008.13 Interpretative breakpoints have 
not yet been established for amphotericin B, but break-
points proposed by Nguyen et al. were used to classified 
strains.21 For posaconazole there is not an established 
interpretative breakpoint yet.
Quality control
Quality control was assured by testing the strains rec-
ommended by CLSI Candida krusei ATCC 6258 and 
Candida parapsilosis ATCC 22019 in each batch of MIC 
testing.13
Statistical analysis
The incidence rates were calculated as the number of 
candidemia episodes per 1,000 admissions and per 1,000 
patient-days. Categorical data were analyzed using Chi-
square and Fisher’s exact tests, as appropriate. A p val-
ue ≤ 0.05 was considered statistically significant. Data 
analyses were performed by Epi-Info 6.04 software CDC 
(Centers for Disease Control and Prevention).
Candidemia epidemiology and susceptibility profi le in the largest Brazilian teaching hospital complex 
443Braz J Infect Dis 2010; 14(5):441-448
Motta, Almeida, Almeida Jr et al.
RESULTS
During 2006, the prevalence of fungi and Candida spp. in 
positive blood cultures were 4% and 3.5% respectively, being 
86.1% of fungemia related to Candida species. One hundred 
and thirty six candidemia episodes were identifi ed in 132 
patients. The overall incidence of candidemia was 1.87 per 
1,000 admissions and 0.27 per 1,000 patient days. There was 
a wide variation of incidence rates among hospitals from the 
HC complex ranging from 0.0 to 7.6 cases per 1,000 admis-
sions (Table 1). Seventy seven patients (59.9%) were male, 
and the median age was 40 years old (0-87 years). Fifty one 
patients were children, and 62.7% had less than one year old. 
Among adult patients (> 16 years old) the median age was 
54 years, and 3 months old among children (0-16 years old); 
91% of patients were hospitalized. Of these, 56.5% were in 
clinical wards, 26.3% in intensive care units, and 17.2% in 
surgical wards. The majority of patients had an underlying 
disease, being malignancy the most frequent one (32.5%) 
(Table 2). Among children younger than one year, prematu-
rity was observed in 56.2% of candidemia cases.
Table 2. Candidemia in Hospital das Clínicas complex – Underline disease and distribution among C. albicans 
and other Candida species
Underline disease C. albicans (71) non albicans C (65) Total p-value
Solid Cancer 14 11 25 0.67
Prematurity 9 9 18 0.84
Hematologic malignancy 7 10 17 0.33
Cardiac disease 8 6 14 0.69
Neurologic disease 4 4 8 0.89
Organ transplant 4 3 7 0.79
Autoimmune disease 3 3 6 0.91
Gastrointestinal disease 4 2 6 0.47
Pulmonary disease 4 1 5 0.20
Vascular disease 1 3 4 0.27
HIV 2 2 4 0.93
Politrauma 3 1 4 0.35
Genetic – Hereditary disease 2 1 3 0.61
Skin and soft tissue disease 1 4 5 0.14
Renal disease 2 0 2 0.17
Tuberculosis 1 0 1 0.33
Diabetes Mellitus 1 0 1 0.33
Non evaluated 1 5 6 NA
Table 1. Candidemia: Incidence rates and species distribution in different hospitals from Hospital das Clínicas 
complex from January to December 2006
Candida spp
 General hosp Pediatric hosp Cardiac hosp Ortopedic hosp  Axiliary 1 hosp Axiliary 2 hosp  Total
 ADM Pat/day ADM Pat/day ADM Pat/day ADM Pat/day ADM Pat/day ADM Pat/day ADM Pat/day
C. albicans (66) 1.01 0.15 3.63 0.55 0.91 0.31 0.38 0.05 0 0 2.37 0.03 1.0 0.17
C. parapsilosis (26) 0.27 0.05 2.90 0.44 0.30 0.10 0 0 0.39 0.03 0 0 0.37 0.05
C. tropicalis (18) 0.25 0.04 0.73 0.11 0.38 0.12 0 0 0.39 0.03 0 0 0.28 0.04
C. glabrata (9) 0.20 0.03 0 0 0.08 0.02 0 0 0 0 0 0 0.14 0.02
C. krusei (2) 0.03 0 0 0 0.08 0.02 0 0 0 0 0 0 0.03 0.004
C. guilliermondii (1) 0.03 0 0 0 0 0 0 0 0 0 0 0 0.02 0.002
C. lusitaneae (1) 0.03 0 0 0 0 0 0 0 0 0 0 0 0.02 0.002
C. pelliculosa (1) 0 0 0 0 0 0 0.18 0.03 0 0 0 0 0.02 0.002
C. utilis (1) 0.03 0 0 0 0 0 0 0 0 0 0 0 0.02 0.002
Total (125) 1.85 0.27 7.26 1.10 1.75 0.57 0.56 0.08 0.78 0.06 2.37 0.03 1.87 0.27
Admission (ADM) 39,397 2,755 13,113 5,313 2,563 422 65,276
Patient days (pat/day) 265,774 1,8251 40,585 38,369 33,936 39,887 455,546
Hosp, hospital.
444
The most frequent specie was C. albicans (52.2%), 
followed by C. parapsilosis (22.1%), C. tropicalis (14.7%), 
C. glabrata (6.6%), and C. krusei (1.6%). Table 3 sum-
marizes the species’ distribution. Differences in species 
distribution among non-C. albicans were seen in the 
facility type (Table 1), patient location, and age group 
(Table 4).
Antifungal susceptibility testing (AFST) was per-
formed among 100 Candida spp. (56 C. albicans, 21 C. 
parapsilosis, 14 C. tropicalis, 4 C. glabrata, 2 C. krusei, 
and 1 isolate each of C. guilliermondii, C. lusitaneae, and 
C. pelliculosa) as 36 isolates lost viability. Table 5 sum-
marizes in vitro Candida spp. susceptibilities rates, MIC, 
MIC
50
 and MIC
90
 ranges.
Overall susceptibility to amphotericin B was 100% 
(MIC
50
 0.125 µg/mL / MIC
90
 0.5 µg/mL), for voriconozole 
(MIC
50
 0.008 µg/mL / MIC
90
 0.064 µg/mL), fluconazole 
(MIC
50
 0,25 µg/mL / MIC
90
 4 µg/mL), and caspofungin 
(MIC
50
 0.125 µg/mL / MIC
90 
1 µg/mL) were ≥ 97% for 
itraconazole (MIC
50
 0.032 µg/mL/MIC
90
 0.5 µg/mL); 
the susceptibility rate was 81%. Decreased susceptibil-
ity to caspofungin was seen with 9.5% of C. parapsilosis 
(2/21 isolates with MICs 4 µg/mL). All C. albicans, C. 
tropicalis and C. parapsilosis. C. glabrata and C. krusei 
were susceptible to fluconazole, but one of each, had de-
creased susceptibility to fluconazole. Decreased suscep-
tibility to itraconazole was seen in 12.5% of C. albicans; 
23.8%, of C. parapsilosis; 21.4% of C. tropicalis, 75% 
ofC. glabrata (3/4 isolates) and 100% of C. gulliermon-
dii (1/1 isolate). Voriconazole had good in vitro activ-
ity, but a MIC of 4 µg/mL in one C. glabrata isolate was 
recorded. Posaconazole exhibited low MICs for all iso-
lates, except one C. gulliermondii (32 µg/mL) and one 
C. glabrata (4 µg/mL).
Table 3. Distribution of Candida species isolates from blood culture in Hospital das Clínicas complex from 
January to December 2006
Candida spp n %
C. albicans 71 52.2%
C. parapsilosis 30 22.1% 
C. tropicalis 20 14.8%
C. glabrata 9 6.6%
C. krusei 2 1.5%
C. guilliermondii 1 0.7%
C. lusitaneae 1 0.7%
C. pelliculosa 1 0.7%
C. utilis 1 0.7%
Total 136 100.0%
Table 4. Distribution of Candida species and candidemia cases by age group in Hospital das Clínicas complex 
from January to December 2006
Candida spp < 1 > 1 to < 15  > 16 to < 64 > 65 Total
 n % n % n % n % n %
Distribution of 
32 23.5% 19 14.0% 65 47.8% 20 14.7% 136 100.0%
candidemias by age groups 
C. albicans (71) 16 50.0% 9 47.4% 36 55.4% 10 50.0% 71 52.2%
C. parapsilosis (30) 15 46.9% 4 21.1% 9 13.9% 2 13.9% 30 22.1%
C. tropicalis (20) 0 0.0% 5 26.3% 10 15.4% 5 25.0% 20 14.7%
C. glabrata (9) 1 3.1% 0 0.0% 6 9.2% 2 10.0% 9 6.6%
C. krusei (2) 0 0.0% 0 0.0% 2 3.1% 0 0.0% 2 1.6%
C. guilliermondii (1) 0 0.0% 0 0.0% 0 0.0% 1 5.0% 1 0.7%
C. lusitaneae (1) 0 0.0% 1 5.2% 0 0.0% 0 0.0% 1 0.7%
C. pelliculosa (1) 0 0.0% 0 0.0% 1 1.5% 0 0.0% 1 0.7%
C. utilis (1) 0 0.0% 0 0.0% 1 1.5% 0 0.0% 1 0.7%
Total (136) 32 100.0% 19 100.0% 65 100.0% 20 100.0% 136 100.0%
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Table 5. Antifungal susceptbility testing of 100 Candida spp. isolated from blood culture in Hospital das Clíni-
cas complex from January to December of 2006
Specie (n) S SDD R MIC90 MIC50 Range
Drogas n (%) n (%) n (%) µg/mL µg/mL µg/mL
C. albicans (56)
 Amphotericin B 56 (100)  0 (0) 0 (0) 0.5 0.125 0.016 - 1
 Caspofungin 56 (100) 0 (0) 0 (0) 1 0.125 0.016 - 1
 Fluconazole 56 (100) 0 (0) 0 (0) 0.5 0.125 0.125 - 4
 Itraconazole 49 (87.5) 6 (10.7) 1 (1.8) 0.25 0.016 0.008 - 1
 Voriconazole 56 (100) 0 (0) 0 (0) 0.064 0.008 0.008 - 0.125
 Posaconazole NC NC NC 0.064 0.008 0.008 - 0.064
C. parapsilosis (21)
 Amphotericin B 21 (100) 0 (0) 0 (0) 0.125 0.125 0.032 - 0.5
 Caspofungin 19 (90.5) 0 (0) 2 (9.5) 2 1 0.064 - 4
 Fluconazole 21 (100) 0 (0) 0 (0) 4 0.5 0.125 - 8
 Itraconazole 16 (76.2) 3 (14.3) 2 (9.5) 0.5 0.032 0.008 - 1
 Voriconazole 21 (100) 0 (0) 0 (0) 0.064 0.016 0.008 - 0.125
 Posaconazole NA NA NA 0.25 0.016 0.016 - 0.5
C. tropicalis (14)
 Amphotericin B 14 (100) 0 (0) 0 (0) 1 0.125 0.016-1
 Caspofungin 14 (100) 0 (0) 0 (0) 1 0.125 0.064 - 2
 Fluconazole 14 (100) 0(0) 0 (0) 1 0.25 0.125 - 1
 Itraconazole 11 (78.6) 1 (7.1) 2 (14.3) 1 0.016 0.008 - 32
 Voriconazole 14 (100) 0 (0) 0 (0) 0.032 0.016 0.008 - 0.032
 Posaconazole NA NA NA 0.25 0.064 0.008 - 0.125
C. glabrata (4)
 Amphotericin B 4 (100) 0 (0) 0 (0) 1 - 0.125 - 1
 Caspofungin 4 (100) 0 (0) 0 (0) 1 - 0.125 - 1
 Fluconazole 2 (50) 1 (25.0) 1 (25.0) 256 - 0.125 - 256
 Itraconazole 1 (25.0) 0 (0) 3 (75.0) 32 - 0.016 - 32
 Voriconazole 3 (75.0) 0 (0) 1 (25.0) 0.125 - 0.008 - 4
 Posaconazole NA NA NA 32 - 0.008 - 32
C. krusei (2)
 Amphotericin B 2 (100) 0 (0) 0 (0) 0.25 - 0.032 - 0.25
 Caspofungin 2 (100) 0 (0) 0 (0) 0.5 - 0.064 - 0.5
 Fluconazole 1 (50) 0 (0) 1 (50) 64 - 0.125 - 64
 Itraconazole 2 (100) 0 (0) 0 (0) 0.125 - 0.016 - 0.125
 Voriconazole 2 (100) 0 (0) 0 (0) 0.125 - 0.008 - 0.125
 Posaconazole NA NA NA 0.25 - 0.064 - 0.25
Others (3)
 Amphotericin B 3 (100) 0 (0) 0 (0) 0.5 - 0.016 - 0.5
 Caspofungin 3 (100) 0 (0) 0 (0) 2 - 0.016 - 2
 Fluconazole 3 (100) 0 (0) 0 (0) 4 - 0.032 - 4
 Itraconazole 2 (66.7) 0 (0) 1 (33.3) 32 - 0.008 - 32
 Voriconazole 3 (100) 0 (0) 0 (0) 0.064 - 0.008 - 0.064
 Posaconazole NA NA NA 4 - 0.008 - 4
Total (100)
 Amphotericin B 100 (100) 0 (0) 0 (0) 0.5 0.125 0.016 - 1
 Caspofungin 98 (98.0) 0 (0) 2 (2.0) 1 0.125 0.016 - 4
 Fluconazole 97 (97.0) 1 (1.0) 2 (2.0) 4 0.25 0.125 - 256
 Itraconazole 81 (81.0) 10 (10) 9 (9.0) 0.5 0.032 0.008 - 32
 Voriconazole 99 (99.0) 0 (0) 1 (1.0) 0.064 0.008 0.008 - 4
 Posaconazole NA NA NA 0.25 0.016 0.008 - 32
Note: S, suceptible; SDD, susceptible dose dependent; R, resistant. Breakpoints according to CLSI M27 A3.
NA, categorical results not applicable. Others C guilliermondii; C. lusitaneae; C. pelliculosa. MIC 90 was not calculated when the 
number of isolates tested was < 10.
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DISCUSSION
Candidemia remains a persistent challenge in many hospi-
tals worldwide leading to signifi cant mortality and overload 
of healthcare costs. There is a wide variation in the incidence 
of candidemia reported in the literature underscoring the 
need for local and global epidemiological studies.
The prevalence of Candida spp. among blood cultures, 
in our study period, was 3.5%, being the ninth most com-
mon isolated microorganism from blood cultures, differing 
from other studies were this microorganism was listed as the 
5th most frequent one.1,4,6
The overall incidence rate (1.87 cases/1,000 admissions) 
was similar to previous Brazilian reports with rates ranging 
from 1.66 to 2.49 cases per 1,000 admissions when com-
paring different hospitals from the HCFMUSP complex.6,22 
Important differences were seen among the hospitals, prob-
ably reﬂ ecting distinct patient populations and differences 
in risk factors. Reports from Canada, USA and Europe 
showed a much lower incidence in candidemia rates, rang-
ing from 0.045 to 0.38 cases per 1,000 admissions.23,27 The 
high rates of candidemia in Brazilian public hospitals were 
highlightened by Colombo et al. in a multicenter study and 
were multifactor related, such as diffi culties in implement-
ing hospital infection control measures, limited number of 
health care workers, and less aggressive antifungal prophy-
laxis practices.6,22
C. albicans was the specie most frequently isolated fol-
lowed by C. parapsilosis, C. tropicalis and C. glabrata. This 
fi nding is consistent with national and Latin American 
studies.6,22,28,29 However, important differences of species 
distribution have been documented when evaluating by age 
group and clinical wards (nurses or ICU). Of note, C. parap-
silosis was the most prevalent non-C. albicans species, prob-
ably because a high proportion of children younger than 1 
year old accounted for almost 25% of cases. C. parapsilosis 
is commonly linked to prematurity, use of central venous 
catheter, and parenteral nutrition.1,30,32 Among patients with 
more than one year old C. tropicalis was the most common 
non-C. albicans species.
C. glabrata was the second non-C. albicans in ICU and 
deserves attention. C. glabrata and C. krusei have been an 
infrequent cause of candidemia in Brazil. Data from USA 
and European countries showed C. glabrata and C. parapsi-
losis as the most prevalent non-C. albicans species.1,4,23,24 The 
reasons for this variation are still not clear, but exposure to 
azoles, subjacent diseases, age group, ward location, and use 
of medical devices could explain these differences.1 Reports 
that evaluated the use of azoles as a risk factor associated with 
non- C. albicans candidemia that are intrinsically resistant or 
with reduced resistance to those drugs, such as C. krusei and 
C. glabrata, remain controversial.1,3,24,33-34 Girão et al. evalu-
ated candidemia rates from one ICU in our hospital over a 
seven year period and did not fi nd an increase in C. glabrata 
and/or C. krusei [incidence], despite increasing ﬂ uconazole 
use during this time. On the other hand, Pasqualotto et al. 
demonstrated an association between ﬂ uconazole use and 
higher incidence rates of C. glabrata fungemia.35
Antifungal susceptibility testing as a routine procedure, 
is an important tool to guide therapeutical choices and 
monitor local resistance. AFST strips by Etest are a validat-
ed agar based methodology that may be an alternative, be-
cause it is relatively easy to perform, with drug choice ﬂ ex-
ibility, and have very good consistency with the reference 
methodology.14-20 Occasionally category discordances be-
tween Etest and the microdilution method may occur due 
to the heteroresistance and trailing phenomenon, generat-
ing higher MICs. These factors were mainly observed with 
C. tropicalis for itraconazole and ﬂ uconazole, and with C. 
glabrata for ﬂ uconazole. Some authors demonstrated that 
heteroresistance detection was possible only with the use 
of Etest and that the reference methodology was unable to 
highlight this phenomenon.14
Similar to other national and international studies, 
antifungal resistance was a rare event. We did not find 
any Candida spp. with MICs >1 µg/mL for amphotericin 
B, and 98% were susceptible to caspofungin, with two C. 
parapsilosis isolates with a MIC of 4 µg/mL. Pfaller et al. 
evaluated 5,346 Candida spp. isolates and found a sus-
ceptibility rate of 99% to echinocandins. However, the 
MIC90 for C. parapsilosis was higher than other Candida 
species, and the reduced susceptibility mechanism is re-
lated to amino acid changes within the FKS1 in a hot spot 
region.36,38
Fluconazole resistant isolates were restricted to C. gla-
brata and C. krusei. The susceptibility profi le to ﬂ uconazole 
was (97%), similar to other Brazilian and Latin American 
studies.6,22,29,39-40,42 European and North American studies 
have showed lower sensitivity, rates ranging from 86.6 to 
95.8%.39,43 C. krusei, despite its known intrinsic resistance 
to ﬂ uconazole, may show false in vitro susceptibility and 
care should be taken to report those results.
For itraconazole, the percentage of non-susceptible 
isolates was 19% (10% SDD and 9% R). Higher itracona-
zole MICs may be associated to technical errors in the MIC 
readings due to the trailing phenomenon.14 The trailing 
phenomenon is most often encountered with azoles and 
is characterized by incomplete growth inhibition. With ap-
propriate training, reading errors should be minimal.
Voriconazole overall susceptibility was high and the 
only resistant strain was one C. glabrata (MIC of 4 µg/mL) 
that showed cross-resistance to all azoles.
There are no official breakpoints for posaconazole, 
but the MIC90 (0.25 µg/mL) was much lower than previ-
ously reported by other authors.20,42,44 Of note, one isolate 
of C. glabrata and one of C. guilliermondii had a very high 
MIC (4 µg/mL).
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Candidemia has a high incidence in our institution 
and despite low resistant rates it poses a therapeutic chal-
lenge, especially among non-C. albicans species. Knowl-
edge of local epidemiology and AFST profile may help 
physicians in selecting the appropriate therapy. Etest of-
fers a validated alternative methodology for routine use 
in clinical laboratories, especially in countries where 
commercial microdilution panels are not available. Con-
tinuous surveillance to monitor trends in incidence, spe-
cies distribution, and antifungal drug susceptibility pro-
files, should be performed at a local and global level, since 
epidemiological studies continue to reveal variations in 
candidemia epidemiology.
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